Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60–85 years in a randomized, double-blind, phase 1 study
ExPEC10V medium- and high-doses were well tolerated with an acceptable safety profile without any significant safety issues in healthy Japanese participants.
Authors
- Miwa Haranaka (ORCID: https://orcid.org/0000-0001-6813-3131)
- Michal Sarnecki (ORCID: https://orcid.org/0000-0001-7035-0020)
- Jan Poolman (ORCID: https://orcid.org/0000-0002-9583-8126)
- Germie van den Dobbelsteen
- Todd A. Davies
- Yoshikazu Nakayama (ORCID: https://orcid.org/0000-0002-2097-3761)
- Atsushi Momose
- Yuki Saito
- Bart Spiessens
Institutions
- Janssen (Belgium) (BE)
- Human Vaccines Project Europe (NL)
- Janssen (Switzerland) (CH)
- SOUSEIKAI Global Clinical Research Center (JP)
- Janssen (United States) (US)
- Janssen (Netherlands) (NL)
Publication Details
- Journal
- Journal of Infection and Chemotherapy
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1016/j.jiac.2024.09.003
- Primary Topic
- Escherichia coli research studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00